Matinas BioPharma provides update from Compassionate/EUA Program with MAT2203

Matinas BioPharma provided an update from its ongoing Compassionate/Expanded Use Access Program with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B. To date, 19 patients have been enrolled in the Program at prestigious healthcare institutions, including the University of Michigan, Johns Hopkins, Nationwide Children’s Hospital, City of Hope, Vanderbilt University Medical Center, the National Institutes of Health, Children’s Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and the University of California, San Diego School of Medicine. The majority of enrolled patients are post-transplant or are undergoing treatment for underlying malignancies. The infections being treated with MAT2203 include a variety of micro-organisms occurring at multiple sites of infection, including brain, bladder/colon, bone, lung, sinus, and skin. Most patients were receiving AmBisome prior to enrollment but developed treatment-limiting nephrotoxicity and most also required treatment for either azole-resistant organisms or had clinically failed azole therapy and had no other treatment options. Of the 19 patients enrolled in the Program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2203. 12 of the 15 patients had either complete clinical resolution or objective improvement in clinical markers of infection. Of the 5 patients who completed their full individually specified course of treatment all have had complete clinical resolution with no relapses or recurrence of their infection. 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned. 5 of the 15 patients were unable to complete their individually specified course of treatment, although 2 saw significant clinical improvement of their fungal infection and are included in the 12 overall successful cases. 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease. 1 patient discontinued therapy after two days due to underlying GI issues. 1 patient passed away due to progression of their underlying disease approximately 8 weeks into therapy. 1 patient discontinued MAT2203 treatment following 10 weeks of therapy due to underlying GI issues but with improvement in their fungal infection. Importantly, all patients who experienced renal toxicity following treatment with AmBisome saw their renal function return to baseline after transitioning to MAT2203 therapy and suffered no further renal side effects over the course of extended treatment with MAT2203.